LPL Receptor Inhibitor

LPL Receptor Inhibitors (24):

Cat. No.	Product Name	Effect	Purity

HY-19989A

MK-571 sodium	Inhibitor	99.24%
MK-571 (L-660711) sodium is an orally active, potent and selective competitive leukotriene D₄ (LTD₄) receptor antagonist, with K_i values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 sodium is also a inhibitor of multidrug resistance-associated protein MRP4 (ABCC4) and ABCC1 (MRP1). MK-571 sodium inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release.

HY-D1005

Poloxamer 407 (F127)	Inhibitor
Poloxamer 407 (F127) is a nonionic surfactant that is 100% active and relatively non-toxic to cells at low concentrations, and frequently used with dye AM esters such as Indo-1 AM, Fura-2 AM, Calcein AM, Fluo-3 AM, Fluo-4 AM, Quest Fluo-8™ AM and Quest Rhod-4™ AM, etc. to improve their water solubility. Poloxamer 407 is also a lipoprotein lipase inhibitor.

HY-156408

Spns2-IN-1	Inhibitor
Spns2-IN-1 is a potent inhibitor of Spns2-dependent S1P transport (Spns2), with IC₅₀ of 1.4±0.3 μM that plays an important role in immune response.

HY-15425A

PF-543 Citrate	Inhibitor	99.33%
PF-543 Citrate (Sphingosine Kinase 1 Inhibitor II Citrate) is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC₅₀ of 2 nM and a K_i of 3.6 nM. PF-543 Citrate is >100-fold selectivity for SPHK1 over SPHK2. PF-543 Citrate is an effective potent inhibitor of sphingosine 1-phosphate (S1P) formation in whole blood with an IC₅₀ of 26.7 nM. PF-543 Citrate induces apoptosis, necrosis, and autophagy.

HY-149004

SLF1081851	Inhibitor	98.11%
SLF1081851 is a Spns2 inhibitor, inhibits S1P release (IC₅₀=1.93 μM). SLF1081851 plays a key role in development and immune system.

HY-15425

PF-543	Inhibitor	99.39%
PF-543 (Sphingosine Kinase 1 Inhibitor II) is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC₅₀ of 2 nM and a K_i of 3.6 nM. PF-543 is >100-fold selectivity for SPHK1 over SPHK2. PF-543 is an effective potent inhibitor of sphingosine 1-phosphate (S1P) formation in whole blood with an IC₅₀ of 26.7 nM. PF-543 induces apoptosis, necrosis, and autophagy.

HY-116147

Ceranib-2	Inhibitor	99.25%
Ceranib-2 is a potent and nonlipid ceramidase inhibitor that inhibits cellular ceramidase activity with an IC₅₀ of 28 μM in SKOV3 cells. Ceranib-2 induces the accumulation of multiple ceramide species, decreases levels of sphingosine and sphingosine-1-phosphate (S1P), and induces cell apoptosis. Anticancer activity.

HY-16040

AM095 free acid	Inhibitor	98.24%
AM095 (free acid) is a potent LPA1 receptor antagonist with IC₅₀ values of 0.98 and 0.73 μM for recombinant human or mouse LPA1 respectively.

HY-18075

LPA2 antagonist 1	Inhibitor	99.56%
LPA2 antagonist 1 is a LPA2 antagonist with an IC₅₀ of 17 nM.

HY-100619A

BMS-986020 sodium	Inhibitor	98.92%
BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist. BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC₅₀s of 4.8 µM, 6.2 µM, and 7.5 µM for BSEP, MRP4, and MDR3, respectively. BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF).

HY-N2553

4-Deoxypyridoxine 5'-phosphate	Inhibitor	≥98.0%
4-Deoxypyridoxine 5'-phosphate is a Pyridoxal 5'-phosphate analogue and a sphingosine 1-phosphate (S1P) inhibitor. 4-Deoxypyridoxine 5'-phosphate inhibits ornithine decarboxylase activity with a K_i of 60 μM. 4-Deoxypyridoxine 5'-phosphate is a competitive inhibitor of the activation of glutamate apodecarboxylase by Pyridoxal 5'-phosphate (K_i of 0.27 μM) and strongly inhibits glutamate-dependent labeling of glutamate decarboxylase.

HY-117444

ONO-9780307	Inhibitor	99.34%
ONO-9780307 is a specific synthetic LPA1 (lysophosphatidic acid receptor 1) antagonist with an IC₅₀ value of 2.7 nM.

HY-150254A

SLB1122168 formic	Inhibitor	99.91%
SLB1122168 formic is a potent Spns2-mediated S1P release inhibitor with an IC₅₀ of 94 nM.

HY-P99318

Sonepcizumab	Inhibitor
Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC).

HY-126145

S1PR1 modulator 1	Inhibitor	99.44%
S1PR1 modulator 1 is a selective S1PR1 inhibitor, with a pIC₅₀ of 7.6, with >40- and >80-fold selectivity, over the other S1PR isoforms S1PR2/3/4.

HY-117959

TAK-615	Inhibitor	98.97%
TAK-615 is a negative allosteric modulator (NAM) of the LPA1 receptor for the research of pulmonary fibrosis. TAK-615 binds the LPA1 receptor with high affinity (K_d high affinity of 1.7 nM and K_d low affinity of 14.5 nM).

HY-150254

SLB1122168	Inhibitor
SLB1122168 is a potent Spns2-mediated S1P release inhibitor with an IC₅₀ of 94 nM.

HY-139094

A6770	Inhibitor	≥99.0%
A6770 is an orally active, potent sphingosine 1-phosphate (S1P) lyase (S1PL) inhibitor. A6770 is phosphorylated and the phosphorylated form directly inhibits S1P lyased.A6770, a potential key metabolite of THI, induces a [³H]dhS1P increase.

HY-15425B

PF-543 hydrochloride	Inhibitor
PF-543 hydrochloride (Sphingosine Kinase 1 Inhibitor II hydrochloride) is a potent, selective, reversible and sphingosine-competitive SPHK1 inhibitor with an IC₅₀ of 2 nM and a K_i of 3.6 nM. PF-543 hydrochloride is >100-fold selectivity for SPHK1 over SPHK2. PF-543 hydrochloride is an effective potent inhibitor of sphingosine 1-phosphate (S1P) formation in whole blood with an IC₅₀ of 26.7 nM. PF-543 hydrochloride induces apoptosis, necrosis, and autophagy.

HY-19989

MK-571	Inhibitor
MK-571 (L-660711) is an orally active, potent and selective competitive leukotriene D₄ (LTD₄) receptor antagonist, with K_i values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 is also a MRP4 and ABCC1 (MRP1) inhibitor. MK-571 inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release.

Name
Email *

	Sorry, but the email address you supplied was invalid.